NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Featured in ROTH Equity Research Report
INmune Bio (NASDAQ: INMB) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Last week, we hosted INMB management meetings in New York and conclude that even early clinical success with any one of its programs would justify our valuation. We view INMB's DN-TNF platform to be a highly rational and safe approach to several diseases that are increasingly associated with surreptitious chronic inflammation. Earlier stage cancer therapy INKmune has advantages to other NK cell therapies including no removal of patient NK cells, a one size fits all approach, and substantially lower…







